Reyes-González, J.M.; Quiñones-Díaz, B.I.; Santana, Y.; Báez-Vega, P.M.; Soto, D.; Valiyeva, F.; Marcos-Martínez, M.J.; Fernández-de Thomas, R.J.; Vivas-Mejía, P.E.
Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer. Cancers 2020, 12, 880.
https://doi.org/10.3390/cancers12040880
AMA Style
Reyes-González JM, Quiñones-Díaz BI, Santana Y, Báez-Vega PM, Soto D, Valiyeva F, Marcos-Martínez MJ, Fernández-de Thomas RJ, Vivas-Mejía PE.
Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer. Cancers. 2020; 12(4):880.
https://doi.org/10.3390/cancers12040880
Chicago/Turabian Style
Reyes-González, Jeyshka M., Blanca I. Quiñones-Díaz, Yasmarie Santana, Perla M. Báez-Vega, Daniel Soto, Fatima Valiyeva, María J. Marcos-Martínez, Ricardo J. Fernández-de Thomas, and Pablo E. Vivas-Mejía.
2020. "Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer" Cancers 12, no. 4: 880.
https://doi.org/10.3390/cancers12040880
APA Style
Reyes-González, J. M., Quiñones-Díaz, B. I., Santana, Y., Báez-Vega, P. M., Soto, D., Valiyeva, F., Marcos-Martínez, M. J., Fernández-de Thomas, R. J., & Vivas-Mejía, P. E.
(2020). Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer. Cancers, 12(4), 880.
https://doi.org/10.3390/cancers12040880